A diabetes-resistant recombinant congenic developed by introgressing selected markers of resistance alleles for all but one known diabesity QTL in the parental strains NZO/HlLt and NON/Lt.  The NONcNZO5/LtJ stock has been specifically constructed to exclude 5 NZO-derived and two NON-derived diabetes susceptibility QTL present in the highly diabetes-prone NONcNZO10LtJ recombinant congenic stock.  NONcNZO5/LtJ males develop a comparable level of moderate obesity to that developing in the highly diabetes susceptible NONcNZO10/LtJ males, but they do not develop the extreme obesity characteristic of NZO/HlLt.  Neither NONcNZO5/LtJ males nor females develop spontaneous type 2 diabetes on a 6% fat-containing diet.  Serum insulin and leptin values are close to the NON/Lt parental background range and significantly lower than in NZO/HlLt.  Unlike NZO/HlLt, NONcNZO5/LtJ breeds well.  Unlike NZO and NONcNZO10/LtJ males, NONcNZO5LtJ males are resistant to adverse hepatic side effects of thiazolidinediones and thus, in combination with NONcNZO10/LtJ mice, may be useful for pharmacogenetic analysis.  This strain represents a model of polygenic obesity and may be used as a diabetes resistant control for NONcNZO10/LtJ (Stock No. 004456).

These RC-5 recombinant congenic mice do not develop spontaneous type 2 diabetes on a 6% fat-containing diet.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.